SCHEMBL6152098

SCHEMBL6152098

Cc1cc(C)c(N)c([C]=O)c1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.45
ALDH1A1 P00352 7/20 0.39
TSHR P16473 2/20 0.39
TDP1 Q9NUW8 2/20 0.39
TP53 P04637 1/20 0.39
CYP3A4 P08684 1/20 0.39
MAPT P10636 2/20 0.37
LMNA P02545 1/20 0.37
GAA P10253 1/20 0.37
POLB P06746 2/20 0.33
NOS3 P29474 1/20 0.32
NOS1 P29475 1/20 0.32
NOS2 P35228 1/20 0.32
RAPGEF4 Q8WZA2 1/20 0.32
HTT P42858 1/20 0.31
SMN1; SMN2 Q16637 2/20 0.31
HSD17B10 Q99714 1/20 0.31
NUDT1 P36639 1/20 0.31
F2 P00734 1/20 0.31
PRSS1 P07477 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28091089 0.79 KDM4E (0.42) KDM4EALDH1A1TSHRTDP1TP53
SCHEMBL27821313 0.78 CYP1A1 (0.36) KDM4EALDH1A1TSHRTDP1TP53
SCHEMBL6589859 0.77 KDM4E (0.41) KDM4EALDH1A1TSHRTDP1TP53
SCHEMBL1312149 0.76 RAPGEF4 (0.35) KDM4EALDH1A1TDP1MAPTLMNA
SCHEMBL139002 0.74 ALDH1A1 (0.65) KDM4EALDH1A1TSHRTDP1TP53
SCHEMBL30578152 0.72 ALDH1A1 (0.61) KDM4EALDH1A1TSHRTDP1TP53
Bromide SCHEMBL29858695 0.72 ALDH1A1 (0.61) KDM4EALDH1A1TSHRTDP1TP53
SCHEMBL28908462 0.72 ALDH1A1 (0.61) KDM4EALDH1A1TSHRTDP1TP53
Hydrochloric Acid SCHEMBL5621296 0.72 ALDH1A1 (0.61) KDM4EALDH1A1TSHRTDP1TP53
Methane SCHEMBL2038793 0.72 ALDH1A1 (0.61) KDM4EALDH1A1TSHRTDP1TP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1494700-A2 CASPASE INHIBITORS FOR THE TREATMENT OF DISEASES AND CONDITIONS CAUSED BY EXPOSURE TO RADIONUCLIDES, BIOLOGICAL AGENTS, OR CHEMICAL AGENTS Cytovia, Inc. (US) 2005-01-12 EP disclosed
WO-2004002401-A2 CASPASE INHIBITORS FOR THE TREATMENT OF DISEASES AND CONDITIONS CAUSED BY EXPOSURE TO RADIONUCLIDES, BIOLOGICAL AGENTS, OR CHEMICAL AGENTS CYTOVIA, INC. (US) 2004-01-08 WO disclosed